Q-omics provides the consensus-scored BCAR3 profile across patient tissues and cancer cell-line models. BCAR3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BCAR3 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, BCAR3 RNA expression shows 19,020 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where BCAR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCAR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCAR3 survival associations across molecular data types. BCAR3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCAR3 RNA expression–survival associations across cancer types. High BCAR3 expression shows unfavorable associations in LUSC, LIHC, PAAD, LUAD and HNSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BCAR3 RNA expression.
This table summarizes BCAR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BCAR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCAR3 shows lower tumor expression in COAD, KIRC, KICH and THCA and higher tumor expression in HNSC and LIHC. The COAD box plot shows higher BCAR3 RNA expression in normal versus tumor tissue (log2 FC = −1.334, t-test p < 0.001).
This table shows molecular features associated with BCAR3 in patient tissues and cancer cell lines. In patient samples, BCAR3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCAR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
